Drugs / UTD1
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05535413 | Jan 2023 → Oct 2024 overdue | Her2-receptor negative breast cancer, metastatic malignant neoplasm in the brain | Hunan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06889610 | Mar 2026 → Dec 2027 expected | colorectal cancer, melanoma, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06385990 | Mar 2024 → Mar 2025 overdue | triple-negative breast carcinoma | Hunan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02253459 | Aug 2014 → Sep 2016 | female breast carcinoma | Beijing Biostar Pharmaceuticals Co., Ltd. | Completed | Met primary |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT06355037 Background | May → Dec 2024 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06355024 Background | May 2024 → Jan 2025 | triple-negative breast carcinoma | Fudan University | Completed | No outcome recorded |
| Phase 3 | NCT05806060 Comparator | Apr 2023 → May 2026 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UTD1 | “Multimodal ablation combined with pucotenlimab and TPC or sacituzumab govitecan, eribulin,gemcitabine,UTD1” NCT06889610 ↗6“UTD1 30mg/m2 d1-5 ivgtt, every 3 weeks” NCT05806060 ↗ |
| Route | Intravenous | “utidelone (30 mg/m2 intravenously once per day on days 1-5)” PMID 28209298 ↗ Feb 2017 |